PARIS--(BUSINESS WIRE)--Regulatory News:
Cellnovo Group (Paris:CLNV) (“Cellnovo” CLNV: EN Paris), a medical technology company marketing the first mobile, connected, all-in-one diabetes management system, announced today that it is partnering with the technology company, TypeZero, to utilise Cellnovo’s e-connected insulin patch pump alongside its inControl AP software in an artificial pancreas (AP) programme. This joint system will be in consideration for use in the International Diabetes Closed Loop Trial (IDCL), which is funded by the National Institute of Health (NIH), a part of the U.S. Department of Health Services.
The artificial pancreas is designed to automatically monitor and regulate blood-sugar levels in people with Type 1 diabetes through the delivery of insulin.
TypeZero’s inControl AP platform was developed based on initial research from the Center for Diabetes Technology at the University of Virginia School of Medicine (UVA). The algorithms at the core of inControl AP have gathered more than 180,000 hours of clinical trial use since 2008. The artificial pancreas system will be using the inControl AP, a Dexcom Continuous Glucose Monitor and the Cellnovo insulin patch pump and mobile connected technology.
The IDCL is expected to enroll 240 adults with Type 1 diabetes and is projected to start in the second half of 2016. Along with the UVA, the artificial pancreas will be tested at nine additional sites: Barbara Davis Center for Diabetes at The University of Colorado, Harvard University, Mayo Clinic, Mount Sinai School of Medicine, Stanford University, William Sansum Diabetes Research Center, University of Montpellier in France, University of Padova in Italy and Academic Medical Center at the University of Amsterdam in The Netherlands.
Sophie Baratte, Chief Executive Officer of Cellnovo, commented: “We are pleased to be working with TypeZero on this key artificial pancreas programme. This is an important milestone as it will be the first time our diabetes management system will be used by American patients taking part in this leading research programme. The Cellnovo Diabetes Management System is the ideal platform for artificial pancreas system development because of its real-time connected data, as well as its wearability and discreetness. The funding by the NIH for the IDCL research programme further demonstrates its key role in AP research.”
Chad Rogers, Founder and CEO of TypeZero Technologies, commented: “The integration of Cellnovo’s insulin patch pump with our inControl AP platform is a tremendous step forward for this artificial pancreas product. We believe that patients should have the choice of using the insulin delivery device that best suits their needs and lifestyle. The Cellnovo pump, with its connected data system and unique combination of patch pump and infusion set, is an amazing option for patients. We look forward to bringing this solution to patients in the upcoming IDCL trial as well as other studies throughout 2016-2017.”
About the Artificial Pancreas System
The artificial pancreas
is designed to automatically monitor and control the blood sugar levels
in people with Type 1 diabetes. The AP system resides on a mobile device
that operates as an intelligent hub to manage a patient’s blood glucose
and insulin pump for optimal control using a set of embedded algorithms.
The artificial pancreas system uses the information from a patient’s
continuous blood glucose monitor (CGM) with an insulin pump to
dramatically reduced average blood glucose while simultaneously
eliminating hypoglycemic events. Today more than 3.5 million people in
North America and Europe have Type 1 Diabetes.
About Cellnovo (Euronext: CLNV)
An international commercial
medical technology company, Cellnovo markets the first mobile, connected
all-in-one diabetes management system, a disruptive technology enhancing
daily disease management for Type 1 diabetes patients. Cellnovo’s device
currently addresses the $2.2 billion insulin pump market and the Company
is reviewing the potential for the device to serve other markets.
Cellnovo is currently marketing the device in the UK, France and The
Netherlands and has a clearly defined commercial and manufacturing
strategy supported by strategic partners Air Liquide and Flextronics.
Cellnovo is headquartered in Paris France with product development
facilities in Wales, UK.
For further information please visit www.cellnovo.com
About the Cellnovo Diabetes Management System
Compact,
tubeless, intuitive and entirely connected, Cellnovo’s insulin pump
comprises a mobile touchscreen controller with an integrated
blood-glucose meter. This unique device allows optimal management of
insulin injections with drop-by-drop precision, whilst ensuring
extensive freedom of movement and peace of mind for patients. Thanks to
the automatic transmission of data, it also allows the patient’s
condition to be continually monitored by family members and healthcare
professionals in real-time.
About TypeZero Technologies
Headquartered in
Charlottesville, Virginia, USA, TypeZero Technologies is a digital
health and technology company specializing in software and analytics
whose mission is to revolutionize the way the world treats and manages
diabetes. TypeZero Technologies applies data-driven analyses and modern
engineering practices to develop personalized analytics and control
solutions based on proven metabolic models to help people with type 1
and type 2 diabetes improve their health reduce the stress of daily
diabetes management, and reduce overall treatment costs. The company’s
products include mobile minute-by-minute closed-loop control of blood
glucose (inControl Artificial Pancreas), cloud-based predictive
analytics, smart bolus calculators, and clinician tools for therapy
optimization. TypeZero Technologies is a rapidly growing private company
currently backed by angel investors and early stage venture capital.
To learn more, visit www.TypeZero.com.
|
Cellnovo is listed on Euronext, Compartment C
ISIN: FR0012633360 – Ticker: CLNV |